X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Why 'pricing' ails Indian pharma... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Nov 27, 2009

    Why 'pricing' ails Indian pharma...

    Pharma major Ranbaxy believes that India's pharma market is potentially among the best markets around the world. In an interview, its CEO Mr. Atul Sobti explains that the Indian healthcare industry could become a major global player. Infact, many times better than the IT industry. It has a lot of opportunities in areas such as in research, development, manufacturing and value-addition. Further, it generates a great deal of employment.

    But due to price controls in the sector, it is not able to realize its full potential. Price controls are meant to keep medicines affordable for the poorer sections of the society. But the flip side is that they keep profitability low and discourage further investment into the sector. A better strategy would be to provide subsidies for those who cannot afford the medicine. That will help keep the rest of the market competitive. In any case, a properly functioning market with strong competition will ensure that prices remain low. A blanket mechanism of price controls leaves little incentive for the players. Mr. Sobti believes that China will again snatch the opportunity from us if we let the situation persist. The dragon nation is already strong in bulk drugs. It is a matter of time before it eyes the formulations pie.

    In our view, the issue boils down to direct versus indirect mechanisms. There is little doubt that direct mechanisms are superior in principle. Think of Income Tax (direct) versus VAT and Excise (indirect). The former is related to the person's ability to pay, the other is blind to the fact. The developed nations rely far more on direct mechanisms - be it in taxes, healthcare or social security. Eventually, we should too.

    Now the buses will run on battery

    The environment is the buzzword at a time when emissions have taken the centre stage of world politics. Automobile companies are among the most directly impacted. As per a leading business daily, India's largest bus manufacturer, Tata Motors, will sell hybrid buses in India in the next few years. The vehicles will be able to switch between diesel and battery. Interestingly, hybrid buses are ideal for intercity traffic. An ideal engine burns a lot of fuel but in case of a hybrid vehicle, it actually recharges the battery. The vehicle can switch over to diesel while travelling at high speeds. In our opinion, the key issue would remain the cost of the vehicle, which is nearly twice the usual amount. Given the price sensitive nature of the Indian auto industry, it will require government assistance for these hybrid buses to get moving.

     

     

    Equitymaster requests your view! Post a comment on "Why 'pricing' ails Indian pharma...". Click here!

    1 Responses to "Why 'pricing' ails Indian pharma..."

    RAMARAO.M

    Dec 6, 2009

    IF WE CAN OVERCOME THE INERTIA IN ISSUANCE OF WHITE RATIONCARDS TO THE REALLY NEEDY AND ARREST ALL LEAKAGES, THEN ALL OTHER REFORMS CAN BE BASED ON THE PROPERLY IDENTIFIED AND NEEDY PEOPLE. PERHAPS THE UNIQUE IDENTITY CARD WILL DO THE TRICK. WE CAME VERY NEAR TO REALLY WEEDINGOUT BOGUS RATION CARDS IN ANDHRA PRADESH, A FEW MONTHS BACK.SUBSIDIES CAN BE TARGETED TO THE WEAKER SECTIONS IF YOU CAN PROVIDE A SECURE BANK ACCOUNT TO EVEN THE HOMELESS. ONLY TECHNOLOGY CAN FIND SOLUTIONS ALONGSIDE LITERACY . IT IS FOR TECHNOLOGY LEADERS TO WORK AT THIS LEAKAGES.

    Like 
      
    Equitymaster requests your view! Post a comment on "Why 'pricing' ails Indian pharma...". Click here!
     

    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    Why Hasn't Warren Buffett Rung the Bell Yet? (The 5 Minute Wrapup)

    Aug 22, 2017

    It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.

    Think Twice Before You Keep Money In A Savings Bank Account (Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    A Darkness Is Spreading Across the US (Vivek Kaul's Diary)

    Aug 22, 2017

    Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working (Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE SENSEX


    Aug 22, 2017 03:36 PM

    MARKET STATS